Exisulind (Aptosyn) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
. HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the...